Crystal S. Shin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Crystal S. Shin has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ghanashyam Acharya
Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
3 shared publications Fernando J. Cabrera
Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, USA
2 shared publications- Adam H. Nelson
Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
1 shared publication Andrew J. Shepherd
Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication- Anthony William Maresso
Department of Molecular Virology and Microbiology, Baylor College of Medicine
1 shared publication Aparna Adumbumkulath
Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, USA
1 shared publication
Latest Publications
- 3 September 2025
- Published by Springer Nature in Pharmaceutical Research
- Vol. 42 (9) , 1573-1585
Local Delivery of Non-opioid Analgesic Microparticles to Modulate Post-surgical Pain
Purpose Postsurgical pain (PSP) is a common complication in surgical patients that can progress to chronic pain and opioid dependence. Current analgesics, including opioids and non-opioid agents, are limited by short durations of action and adverse effects. This study reports the development and evaluation of extended-release bupivacaine microparticles (BuMPs) designed to provide sustained local analgesia and improve post-surgical pain management. Methods BuMPs were fabricated using PLGA and tested in a mouse sciatic nerve injury (SNI) model, a clinically relevant model of neuropathic pain. Mice received a single local injection of BuMPs or blank microparticles. Mechanical hypersensitivity was assessed using the von Frey test over a 21-day period. BuMPs were also compared to an FDA-approved liposomal bupivacaine formulation. Results We fabricated BuMPs by the hydrogel template method and confirmed their uniform size distribution. Thus prepared BuMPs exhibited extended bupivacaine release in vitro and in vivo in a healthy rat model. In a SNI model, BuMP-treated mice exhibited significantly reduced mechanical hypersensitivity compared to controls, with analgesic effects sustained for up to 21 days. BuMPs provided prolonged pain relief, demonstrating effective modulation of postsurgical and neuropathic pain. Conclusions BuMPs offer a promising non-opioid strategy for long-acting PSP management. Their extended analgesic effect from a single perioperative injection may reduce opioid reliance, improve patient recovery, and serve as a complementary therapy.
- 3 September 2025
- Published by Springer Nature in Pharmaceutical Research
- Vol. 42 (9) , 1573-1585
Local Delivery of Non-opioid Analgesic Microparticles to Modulate Post-surgical Pain
Purpose Postsurgical pain (PSP) is a common complication in surgical patients that can progress to chronic pain and opioid dependence. Current analgesics, including opioids and non-opioid agents, are limited by short durations of action and adverse effects. This study reports the development and evaluation of extended-release bupivacaine microparticles (BuMPs) designed to provide sustained local analgesia and improve post-surgical pain management. Methods BuMPs were fabricated using PLGA and tested in a mouse sciatic nerve injury (SNI) model, a clinically relevant model of neuropathic pain. Mice received a single local injection of BuMPs or blank microparticles. Mechanical hypersensitivity was assessed using the von Frey test over a 21-day period. BuMPs were also compared to an FDA-approved liposomal bupivacaine formulation. Results We fabricated BuMPs by the hydrogel template method and confirmed their uniform size distribution. Thus prepared BuMPs exhibited extended bupivacaine release in vitro and in vivo in a healthy rat model. In a SNI model, BuMP-treated mice exhibited significantly reduced mechanical hypersensitivity compared to controls, with analgesic effects sustained for up to 21 days. BuMPs provided prolonged pain relief, demonstrating effective modulation of postsurgical and neuropathic pain. Conclusions BuMPs offer a promising non-opioid strategy for long-acting PSP management. Their extended analgesic effect from a single perioperative injection may reduce opioid reliance, improve patient recovery, and serve as a complementary therapy.
- Open Access
- 10 September 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (9) , 1445
Development of Antimicrobial Nitric Oxide-Releasing Fibers
Nitric oxide (NO) is a highly reactive gas molecule, exhibiting antimicrobial properties. Because of its reactive nature, it is challenging to store and deliver NO efficiently as a therapeutic agent. The objective of this study was to develop NO-releasing polymeric fibers (NO-fibers), as an effective delivery platform for NO. NO-fibers were fabricated with biopolymer solutions of polyvinyl pyrrolidone (PVP) and ethylcellulose (EC), and derivatives of N-diazeniumdiolate (NONOate) as NO donor molecules, using an electrospinning system. We evaluated in vitro NO release kinetics, along with antimicrobial effects and cytotoxicity in microorganisms and human cell culture models. We also studied the long-term stability of NONOates in NO-fibers over 12 months. We demonstrated that the NO-fibers could release NO over 24 h, and showed inhibition of the growth of Pseudomonas aeruginosa (P. aeruginosa) and methicillin-resistant Staphylococcus aureus (MRSA), without causing cytotoxicity in human cells. NO-fibers were able to store NONOates for over 12 months at room temperature. This study presents the development of NO-fibers, and the feasibility of NO-fibers to efficiently store and deliver NO, which can be further developed as a bandage.
- 10 September 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (9) , 1445
Open AccessDevelopment of Antimicrobial Nitric Oxide-Releasing Fibers
Nitric oxide (NO) is a highly reactive gas molecule, exhibiting antimicrobial properties. Because of its reactive nature, it is challenging to store and deliver NO efficiently as a therapeutic agent. The objective of this study was to develop NO-releasing polymeric fibers (NO-fibers), as an effective delivery platform for NO. NO-fibers were fabricated with biopolymer solutions of polyvinyl pyrrolidone (PVP) and ethylcellulose (EC), and derivatives of N-diazeniumdiolate (NONOate) as NO donor molecules, using an electrospinning system. We evaluated in vitro NO release kinetics, along with antimicrobial effects and cytotoxicity in microorganisms and human cell culture models. We also studied the long-term stability of NONOates in NO-fibers over 12 months. We demonstrated that the NO-fibers could release NO over 24 h, and showed inhibition of the growth of Pseudomonas aeruginosa (P. aeruginosa) and methicillin-resistant Staphylococcus aureus (MRSA), without causing cytotoxicity in human cells. NO-fibers were able to store NONOates for over 12 months at room temperature. This study presents the development of NO-fibers, and the feasibility of NO-fibers to efficiently store and deliver NO, which can be further developed as a bandage.
- 1 August 2019
- Published by Elsevier in Drug Discovery Today
- Vol. 24 (8) , 1679-1684
Challenges and opportunities for drug delivery to the posterior of the eye
- 1 August 2019
- Published by Elsevier in Drug Discovery Today
- Vol. 24 (8) , 1679-1684
Challenges and opportunities for drug delivery to the posterior of the eye